Analytical Data
-
Gene name
UGT2B17
- Application
-
Alternative Names
(UDPGT 2B17)(UGT2B17)(C19-steroid-specific UDP-glucuronosyltransferase)(C19-steroid-specific UDPGT)
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O75795
-
Expression Region
24-530aa
-
Molecular Weight
64.5 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
UGT2B17, a member of the UDP-glucuronosyltransferase enzyme family, plays a critical role in the metabolism of various endogenous and exogenous compounds, including drugs, hormones, and environmental toxins, through glucuronidation, a process that enhances their solubility and facilitates excretion. The importance of UGT2B17 in pharmacogenomics is underscored by its genetic variability, which can lead to significant interindividual differences in drug metabolism and response. Research has indicated that certain polymorphisms in the UGT2B17 gene can result in either reduced or enhanced enzymatic activity, thereby influencing the pharmacokinetics of drugs metabolized by this enzyme, such as opioids and antihistamines. Understanding the structure-function relationship of UGT2B17 through the study of its recombinant protein is vital for elucidating its enzymatic mechanisms and potential as a therapeutic target. Moreover, UGT2B17's involvement in the metabolism of steroid hormones, particularly androgens, underscores its relevance in conditions like prostate cancer and other endocrine disorders. Consequently, the recombinant expression and characterization of UGT2B17 can provide insights into its functional properties and aid in the development of personalized medicine strategies, ultimately improving therapeutic outcomes for individuals based on their genetic makeup. Given the implications of UGT2B17 in drug interactions and disease pathogenesis, ongoing research focuses on its functional variants, substrate specificity, and regulatory mechanisms to pave the way for improved disease management and drug development.
